Preventing major adverse cardiovascular events by SGLT-2 inhibition in patients with type 2 diabetes: the role of kidney

Table 1 Main basal risk factors for MACE in the cardiovascular outcome trials testing the effect of SGLT2 inhibition in type 2 diabetes

Trial Sample size	SGLT2-I	Age, years	Smokers, % pts	BMI, kg/m²	Systolic BP, mmHg	HbA1c, %	LDL-C, mg/dL	ACVD, % pts	eGFR, mL/min/1.73 m²	eGFR < 60, % pts	Anti-RAS, % pts	Statin, % pts
EMPA-REG n = 7021	Empa	63 ± 9	13.0	31 ± 5	135 ± 17	8.1 ± 0.9	86 ± 36	89	74 ± 22	26.0	81.0	77.4
CANVAS n = 10,142	Cana	63 ± 8	17.8	32 ± 6	137 ± 16	8.2 ± 0.9	89 ± 35	72	77 ± 21	25.0	80.2	74.7
DECLARE n = 17,160	Dapa	64 ± 7	14.5	32 ± 6	135 ± 15	8.3 ± 1.2	89 ± 35	41	85 ± 16	7.0	81.3	74.9
CREDENCE n = 4401	Cana	63 ± 9	14.5	31 ± 6	140 ± 16	8.3 ± 1.3	96 ± 41	69	56 ± 18	59.8	99.9	69.8

MACE: major adverse cardiovascular evets, that is, cardiovascular death, myocardial infarction, or ischemic stroke; BP: blood pressure; LDL-C: LDL cholesterol; ACVD: atherosclerotic cardiovascular disease; Anti-RAS: inhibitors of renin angiotensin system; CVD: cardiovascular disease; eGFR: estimated glomerular filtration rate

ISSN: 1475-2840